

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078925883

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078925879 078925880 078925881 078925882

Vetprofen**SAFETY DATA SHEET****(1) IDENTIFICATION**

**Name:** Carprofen Caplets (Vetprofen™)

**Use:** Non-narcotic, Non-steroidal anti-inflammatory drug (NSAID) with characteristic Analgesic and antipyretic activity approximately equivalent to indomethacin in animal models.

**Supplier:** Vetoquinol USA  
4250 N. Sylvania Ave  
Fort Worth, TX 76137

**Tel:** (817)529-7500

**Fax:** (817)529-7506

---

**(2) HAZARD(S) IDENTIFICATION**

**Appearance:** Yellow orange, capsule shaped, biconvex caplets scored

**Classification of the Substance or Mixture****GHS - Classification**

Reproductive Toxicity: Category 2

Specific target organ systemic toxicity (repeated exposure): Category 2

**Label Elements**

**Signal Word:** Warning

**Hazard Statements:** H361d - Suspected of damaging the unborn child

H373 - May cause damage to organs through prolonged or repeated exposure

**Precautionary Statements:** P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

**Other Hazards**

**Short Term:** Not expected to cause eye irritation. Not expected to cause skin irritation . (based on components) . May cause allergic skin reaction Anecdotal reports from facilities handling RIMADYL caplets have indicated a potential for workers to develop rashes upon exposure to dusts of the material.

**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, the developing fetus.

(3) **COMPOSITION/INFORMATION ON INGREDIENTS****Common Name: Vetprofen**

**Composition:** Proprietary Ingredients. Ingredients indicated as hazardous have been assessed under standards for workplace safety.

<u>Chemical</u>	<u>% Concentration</u>	<u>CAS</u>
Carprofen	Proprietary	53716-49-7
Microcrystalline Cellulose	Proprietary	9004-34-6
Croscarmellose Sodium	Proprietary	7811-65-7
Magnesium Stearate	Proprietary	557-04-0
Purified Stearic Acid	Proprietary	57-11-4
Yellow #6	Proprietary	2783-94-0

(4) **FIRST AID MEASURES**

**Eye Contact:** Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

**Skin Contact:** Wash skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed Symptoms and Effects of**

**Exposure:**

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions**

**Aggravated by Exposure:**

None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:** None

(5) **FIRE-FIGHTING MEASURES**

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion**

**Products:**

May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

**Fire / Explosion Hazards:** Not applicable

**Advice for Fire-Fighters**

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

---

(6) **ACCIDENTAL RELEASE PROCEDURES**

**Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Methods and Material for Containment and Cleaning Up**

**Measures for Cleaning /**

**Collecting:**

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for**

**Large Spills:**

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

---

(7) **HANDLING AND STORING**

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Conditions for Safe Storage, Including any Incompatibilities**

**Storage Conditions:** Store as directed by product packaging.

**Storage Temperature:** 15 - 30 °C

**Specific end use(s):** No data available

---

(8) **EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Control Parameters:** Refer to available public information for specific member state  
**Occupational Exposure Limits.**

**Engineering measures:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protection:**

**Respiratory:** Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**(9) PHYSICAL AND CHEMICAL PROPERTIES**

<b>Appearance/Odor:</b>	Light Yellow, scored caplets with no odor.
<b>pH:</b>	No Data Available
<b>Boiling point/Range:</b>	No Data Available
<b>Flash Point:</b>	No Data Available
<b>Explosive properties:</b>	No Data Available.
<b>Oxidising properties:</b>	No Data Available
<b>Specific gravity:</b>	No Data Available
<b>Solubility (water at 20°C):</b>	No Data Available

**(10) STABILITY AND REACTIVITY**

<b>Stability:</b>	Stable.
<b>Conditions to avoid:</b>	None known
<b>Materials to avoid:</b>	As a precautionary measure, keep away from strong oxidizers
<b>Hazardous decomposition products:</b>	None

---

**(11) TOXICOLOGICAL INFORMATION****TEST DATA****Acute Toxicity:****Carprofen**

Mouse Oral LD50 282 mg/kg

Rat Oral LD50 149mg/kg

Rat (M/F) IP LD50 140/110 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

Eye Irritation Rabbit Non-irritating

Skin Irritation Rabbit Non-irritating

Skin Sensitization - GPMT Guinea Pig Negative

Antigenicity- Delayed skin reaction Guinea Pig No effect

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

13 Week(s) Rat Oral 5 mg/kg/day NOAEL Gastrointestinal System

13 Week(s) Dog Oral 5 mg/kg/day NOAEL None identified

**Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

Reproductive &amp; Fertility Rat 20 mg/kg/day NOAEL Fetotoxicity, Maternal toxicity

Embryo / Fetal Development Rat 20 mg/kg/day NOAEL Not Teratogenic

Prenatal &amp; Postnatal Development Mouse 40 mg/kg/day NOAEL Not Teratogenic

Prenatal &amp; Postnatal Development Rabbit Oral 6 mg/kg/day NOAEL Embryotoxicity, Early embryonic development

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

---

(12)

**ECOLOGICAL INFORMATION**

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided

**Persistence and degradability:** None noted

**Bioaccumulation:** Not noted.

**Aquatic toxicity:** None noted.

---

(13)

**DISPOSAL CONSIDERATIONS**

**Disposal of product and Packaging:** Dispose of in accordance with all applicable state, local, and federal laws. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

(14)

**TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT.

---

(15)

**REGULATORY INFORMATION**

**Symbol:**



(16)

**OTHER INFORMATION**

**Uses:** Non-narcotic, Non-steroidal anti-inflammatory drug (NSAID) with characteristic Analgesic and antipyretic activity approximately equivalent to indomethacin in animal models.

**Further product information:** Consult Vetprofen Package insert or Vetoquinol USA website [www.vetoquinolUSA.com](http://www.vetoquinolUSA.com) for further information.

**Prepared by:** James Spiezio, DVM  
Scientific Affairs Manager  
Vetoquinol USA

**SDS Dated:** 08 September 2015

**Supersedes:** MSDS dated: October 2015

**TELEPHONE NUMBER:** (817)529-7500